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Cytomegalovirus
Cytomegalovirus (CMV), a human herpesvirus HHV5, is present 
in latent form in 40%–70% children and 60%–90% of adults [1]. In 
patients after allogeneic hematopoietic cell transplantation (allo-HCT), 
it can reactivate either as recipient or donor origin. The virus can 
cause direct and indirect toxicity [2, 3]. Direct effects can cause organ 
infections (enteritis, pneumonia, hepatitis, bone marrow suppression, 
and retinitis) and toxicity, while indirect effects refer to associated 
adverse effects of antiviral therapy and increased risk of bacterial 
and fungal infections, and further suppression of immune system. 
Additionally, CMV seropositive status of recipient and/or donor, CMV 
reactivation, and CMV infection/disease cause decreased survival 
after hematopoietic cell transplantation (HCT) [4, 5, 6]. According 
to current knowledge, guidelines, and clinical experience, the best 
preventive strategy for CMV infection after allo-HCT in the year 2020 
is specific antiviral prophylaxis with letermovir [7, 8, 9]. This drug is 
currently registered worldwide for primary prophylaxis for CMV-
seropositive adults after allo-HCT. The objective of this clinical vignette 
is presentation of safe and efficacious use of letermovir for primary 
prophylaxis of CMV infection in two children after allo-HCT.
Patient 1
A 15-year-old girl, with body weight 58 kg, diagnosed for severe aplastic 
anemia (SAA), after failure of immunoablative therapy with anti-
thymocyte globulin (ATG) + steroids + granulocyte colony stimulating 
factor (GCSF) + romiplostim, was qualified for HCT. Due to lack of sibling 
or matched unrelated donor, a haploidentical mother was selected to be 
the donor. Conditioning (fludarabine (FLU) + cyclophosphamide (CY) 
+ single dose total body irradiation (sTBI) + ATG) and prophylaxis of 
graft-versus-host disease (GVHD) [post-transplant cyclophosphamide 
(PTCy) + cyclosporin A (CsA) + mycophenolate mofetil (MMF)] was 
performed according to Bacigalupo regimen [10]. No acute GVHD 
occurred. Due to CMV seropositivity of donor and recipient, the patient 
was administered prophylactically letermovir, orally from day 1. The 
dosage was 240 mg daily, and the patient was on CsA. The drug was 
well tolerated and no adverse effects were reported. No toxicities of 
ciclosporin A were observed and the CsA levels were stable. Due to 
pneumonia and respiratory insufficiency, the patient died without T-cell 
engraftment on day 60. Polymerase chain reaction (PCR) DNA-emia 
CMV on day 60 was negative (Fig. 1).
Patient 2
A 7-year-old boy, with body weight 27 kg, diagnosed for T-cell acute 
lymphoblastic leukemia (ALL), was qualified for HCT due to lack of 
remission by day 33 preceded by initial poor steroid response and 
presence of minimal residual disease. He was transplanted from 
female matched unrelated donor. Conditioning (total body irradiation 
(TBI) + etoposide) and prophylaxis of GVHD (PTCy + CsA + MMF) 
was performed. No acute GVHD occurred. Due to CMV seropositivity 
of donor and recipient, the patient was administered prophylactically 
letermovir, orally from day 1. The dosage was 120 mg daily, and the 
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PATIENT 2: Male, 7y, 27 kg bw
DIAGNOSIS: ALL, CMV-POS

















Fig 1. Use of letermovir for primary prophylaxis of CMV infection 
in two children
GVHD – graft-versus-host disease; SAA – severe aplastic anemia, CMV-POS - cytomegalovirus-
positive; FLU+CY+sTBI+ATG – fludarabine + cyclophosphamideand +single dose total body 
irradiation + anti-thymocyte globulin;  PTCy+MMF+CsA – post-transplant cyclophosphamide + 
mycophenolate mofetil  + cyclosporin A; MUD – matched unrelated donor;  ALL – T-cell acute 
lymphoblastic leukemia, 
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patient was on cyclosporine A. The drug was well tolerated and no 
adverse effects were reported. No toxicities of CsA were observed 
and the CsA levels were stable. T-cell engraftment (CD4+ >200/µl) 
was reached by day 60, and letermovir was discontinued by day 80, 
PCR DNA-emia CMV on day 90 was negative (Fig. 1).
Discussion
Due to its extremely favorable safety profile, letermovir brings potential 
for the use in clinical situations, other than approved indication. We 
decided to administer letermovir to our two patients being at very high 
risk of CMV reactivation. In Patient 1, we applied typical dosing as for 
adults when concomitantly treated with cyclosporine A. As the patient 
body weight was 58 kg, it was comparable to adults. With pediatric 
approach, the drug was administered at dosage of 4.1 mg/kg bw. In 
Patient 2, with body weight 27 kg, we decided to use letermovir at the 
daily dose of 120 mg, which corresponded to pediatric dosing 4.4 mg/
kg bw. In summary, in both cases the administration of letermovir was 
safe and protected the patients from CMV reactivation, as confirmed 
in several PCR assays.
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